Abstract Details

Title Retinal Inflammation as a Biomarker of Disease Activity in Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 133

Objective

Background BACKGROUND: Retinal periphlebitis (RP) and microcystic macular edema (MME) identified in MS patients may represent breakdown of blood-retinal-barrier due to retinal inflammation by MS. RP and MME have been associated with relapses and greater disability, respectively. We postulated they may be considered as biomarkers of MS.

Design/Methods DESIGN/METHODS: 100 consecutive MS-patients [69 female; 41.35±9.54years; 38 history of acute optic neuritis (AON)] underwent neurological and ophthalmic examinations. Lesion load was quantified using T1MPRAGE sequence (3T-MRI). OCT studies were performed using Spectralis-OCT. RNFL-thickness was considered as mean value of both eyes for no-AON-patients and unaffected eye's value for AON-patients. We compared EDSS, RNFL-thickness and T1-MPRAGE lesion volume among patients with and without retinopathy. After exploring measures by retinal phenotypes, we found differences mainly due to RP group. Therefore, we estimated multivariable-adjusted (sex, age and disease duration) means of these parameters among patients with RP and patients without retinopathy using general linear models.

Results RESULTS: 7 patients had retinopathy (5 with RP and 2 with MME). Patients with retinopathy had higher unadjusted-mean of T1 lesion volume (19,322±16228mm3 vs 9,926±10,696mm3; p=0.033) and lower RNFL thickness (77.71±13.70[mu]m vs 93.27±12.60[mu]m; p=0.002). We found a trend of higher mean EDSS for retinopathy group. Patients with RP showed higher adjusted-mean of T1 lesion volume [20,049 95%CI: 10,293-29,805 vs. 9596 95%CI: 7,272-11,920); p=0.039] and lower adjusted-mean of RNFL-thickness [79.22 95%CI: 68.32-90.12 vs. 92.58 95%CI: 89.99-95.18 p=0.018] than patients without retinopathy. Also, RP patients a not significantly higher EDSS [2.23 95%CI: 1.23-3.22 vs. 1.98 95%CI: 1.75-2.22; p=0.633].

Conclusions CONCLUSIONS: Retinal inflammation, especially RP, was more frequent in patients with more active disease and higher axonal damage supporting its role as biomarker of disease activity in MS.

Authors/Disclosures
PRESENTER	No disclosure on file
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ)	Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clario.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Albert Saiz (Hospital Clinico De Barcelona)	Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janseen. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novartis. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
	No disclosure on file
Pablo Villoslada, MD, PhD, FAAN (Hospital del Mar Research Institute)	Dr. Villoslada has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Oculis. Dr. Villoslada has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bionure. Dr. Villoslada has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telara Therapeutics. Dr. Villoslada has or had stock in Attune Neurosciences.Dr. Villoslada has or had stock in Bionure Therapeutics.Dr. Villoslada has or had stock in Spiral Therapeutics.Dr. Villoslada has or had stock in Adhera Health.Dr. Villoslada has or had stock in Clarity technologies.Dr. Villoslada has or had stock in QMENTA Inc. The institution of Dr. Villoslada has received research support from Start2Cure Foundation. The institution of Dr. Villoslada has received research support from European Commission. The institution of Dr. Villoslada has received research support from Instituto Salud Carlos III. The institution of Dr. Villoslada has received research support from Focused Ultrasound Foundation and ALS Foundation. The institution of Dr. Villoslada has received research support from Caixa Foundation. Dr. Villoslada has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��